-
Signature
-
Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
-
Stock symbol
-
KYTX
-
Transactions as of
-
Feb 12, 2024
-
Transactions value $
-
$20,020,000
-
Form type
-
4
-
Date filed
-
2/13/2024, 05:48 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
KYTX |
Common Stock |
Conversion of derivative security |
|
+3.22M |
|
|
3.22M |
Feb 12, 2024 |
Direct |
F1, F2 |
transaction |
KYTX |
Common Stock |
Purchase |
$20M |
+910K |
+28.29% |
$22.00* |
4.13M |
Feb 12, 2024 |
Direct |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
KYTX |
Series A-2 Convertible Preferred Stock |
Conversion of derivative security |
$0 |
-6.89M |
-100% |
$0.00* |
0 |
Feb 12, 2024 |
Common Stock |
1.51M |
|
Direct |
F1, F2 |
transaction |
KYTX |
Series B Convertible Preferred Stock |
Conversion of derivative security |
$0 |
-7.75M |
-100% |
$0.00* |
0 |
Feb 12, 2024 |
Common Stock |
1.7M |
|
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Gilead Sciences, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses: